In summary, we composed a new risk model of Bcl-6/Peli1 by using E3 ligase Peli1 and its known target, Bcl-6 in the basis of lymphomagenesis, and this model independently predicted prognosis in DLBCL patents for PFS and OS. This evidence concerns the gene PELI1 and diffuse large B-cell lymphoma.